Know Cancer

or
forgot password


N/A
12 Years
60 Years
Open (Enrolling)
Both
Osteosarcoma

Thank you

Trial Information


Inclusion Criteria:



1. Proved by pathology in 60 cases of osteosarcoma patients

2. PS ≤ 2, survival period is more than 6 months

3. Normal function of liver and kidney

4. No chemotherapy contraindication, patients treat with high dose methotrexate

5. Get signed written informed consent form

6. Have a good compliance with take blood and follow-up

Exclusion Criteria:

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

blood concentration of MTX

Outcome Time Frame:

up to 3 years

Safety Issue:

Yes

Principal Investigator

Chen Wang

Investigator Role:

Study Chair

Investigator Affiliation:

Tianjin Medical University Cancer Institute and Hospital

Authority:

United States: Institutional Review Board

Study ID:

CIH-WAC-201205001

NCT ID:

NCT01758666

Start Date:

September 2012

Completion Date:

December 2014

Related Keywords:

  • Osteosarcoma
  • Osteosarcoma

Name

Location